Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Abstract

Summary Introduction The burden of post‐COVID‐19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta‐analysis was to estimate the rate of post‐COVID‐19 FD and IBS. Methods MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID‐19 survivors and controls (without COVID‐19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I2. Results Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID‐19 patients were considered for FD. Post‐COVID‐19 FD was reported by 72 patients (4%, 95% CI: 3%–5% and I2 0%). The pooled OR for FD development (three studies) in post‐COVID‐19 patients compared to controls was 8.07 (95% CI: 0.84–77.87, p = 0.071 and I2 = 67.9%). Overall, 10 studies including 2763 COVID‐19 patients were considered for IBS. Post‐COVID‐19 IBS was reported by 195 patients (12%, 95% CI: 8%–16%, I2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID‐19 patients compared to controls was 6.27 (95% CI: 0.88–44.76, p = 0.067 and I2 = 81.4%); considering only studies with a prospective COVID‐19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58–46.60, p < 0.001 and I2 = 0%). Conclusions COVID‐19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.

Risk factors for irritable bowel syndrome: A review

“…Факторы, значимо связанные с диагнозом СРК, включали аллергию в анамнезе (ОШ 10,024, 95% ДИ 1,766-56,891), хронический прием ингибиторов протонной помпы (ОШ 4,816, 95% ДИ 1,447-16,025) и наличие одышки (ОШ 4,157, 95% ДИ 1,336-12,934). Проведенный позже метаанализ, объединивший данные 10 исследований и 2763 пациентов с COVID-19, показал, что распространенность ПИ-СРК у лиц, перенесших инфекцию, составляет 12% (95% ДИ 8-16), а объединенное ОШ развития СРК, учитывая только исследования с проспективной когортой (три исследования) -12,92, 95% ДИ 3,58-46,60 [79].…”

Letter: Post‐COVID‐19 disorders of gut‐brain interaction (DGBI)—Just post‐infectious or a multi‐faceted entity?

“…We read with interest the recent meta-analysis of 10 studies exploring the prevalence of functional dyspepsia (FD) and irritable bowel syndrome (IBS) in individuals following COVID-19 infection. 1 Marasco et al highlight a significantly higher prevalence of IBS in post-COVID-19 patients compared with controls, and a higher risk of developing IBS in patients with severe COVID-19. This study contributes to the existing data on gastrointestinal (GI) manifestations of Long COVID, a newly minted entity which continues to evolve.…”

Post-COVID-19 irritable bowel syndrome: an integrative review

“…Interestingly, it has been observed that patients previously diagnosed with COVID-19 are at greater risk of developing Irritable Bowel Syndrome (IBS) when compared with uninfected individuals 7 . IBS, in turn, is one of the Gut-Brain Interaction Disorders (GBID), previously called Functional Gastrointestinal Disorders (FGD) 8 .…”